"Potential drug treatments are tested on paper, in laboratories and eventually in thousands of people. But every drug that goes through this cycle â€“ every drug that FDA approves â€“ carries some risk. One of the first lines of defense against "...
The most common adverse reactions associated with Infasurf (calfactant) dosing procedures in the controlled trials were cyanosis (65%), airway obstruction (39%), bradycardia (34%), reflux of surfactant into the endotracheal tube (21%), requirement for manual ventilation (16%), and reintubation (3%). These events were generally transient and not associated with serious complications or death.
The incidence of common complications of prematurity and RDS in the four controlled Infasurf (calfactant) trials are presented in Table 3. Prophylaxis and treatment study results for each surfactant are combined.
Table 3 - Common Complications of Prematurity and RDS in
|Patent ductus arteriosus||47||48||45||48|
|Severe intracranial hemorrhage a||12||10||9||7|
|IVH and PVLb||7||3||5||5|
|Pulmonary air leaks||12||22||15||15|
|Pulmonary interstitial emphysema||7||17||10||10|
|a Grade III and IV by the method of Papile.
b Patients with both intraventricular hemorrhage and periventricular leukomalacia.
Two-year follow-up data of neurodevelopmental outcomes in 415 infants enrolled in 5 centers that participated in the Infasurf (calfactant) vs. Exosurf Neonatal® controlled trials demonstrated significant developmental delays in equal percentages of Infasurf (calfactant) and Exosurf Neonatal® patients.
Read the Infasurf (calfactant) Side Effects Center for a complete guide to possible side effects
No information provided.
Last reviewed on RxList: 5/7/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Infasurf Information
Report Problems to the Food and Drug Administration
Find out what women really need.